Todd Wider
Director/Board Member at ARYA SCIENCES ACQUISITION CORP IV
Net worth: 2 M $ as of 2024-04-29
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Joseph Edelman | M | 67 | 6 years | |
| Michael Altman | M | 42 | 4 years | |
| Adam Stone | M | 44 | 4 years | |
| Konstantin Poukalov | M | 40 | 4 years | |
| Paul Mann | M | 48 |
Varian Biopharmaceuticals, Inc.
 Varian Biopharmaceuticals, Inc. BiotechnologyHealth Technology Part of Healthtech Solutions, Inc., Varian Biopharmaceuticals, Inc. is a private precision oncology company based in Naples, FL. Varian Bio is developing novel therapeutics for the treatment of cancer using precision oncology, which involves DNA testing to identify genetic mutations in tumors for more targeted treatment recommendations. Varian Bio's lead drug candidate, Var-101, is being developed in a topical formulation for the treatment of basal cell carcinoma, while Var-102, an oral formulation, is being developed for the treatment of various solid tumors, including non-small cell lung cancer, pancreatic cancer, and colorectal cancer. Varian Bio is also seeking additional precision oncology therapeutic candidates for its pipeline and exploring development collaborations. The CEO of the company is Jeffrey Blaine Davis. Varian Biopharmaceuticals was acquired by Healthtech Solutions, Inc. on May 07, 2021. | 4 years |
| Bruce Turner | M | 60 |
Xanadu Bio Inc.
| 3 years |
| Pierluigi Paracchi | M | 50 | 10 years | |
| Jake Bauer | M | 45 | 4 years | |
| Robert Ainscow | M | 48 | 3 years | |
| David Baram | M | - |
Emendo Biotherapeutics, Inc.
 Emendo Biotherapeutics, Inc. BiotechnologyHealth Technology Emendo Biotherapeutics, Inc. engages in the development of genome editing technology. It specializes in protein engineering, molecular biology, and gene editing systems. The company was founded by David Baram, Lior Izhar, and Rachel Diamant in 2015 and is headquartered in New York, NY. | 9 years |
| Michael Henderson | M | 34 | 3 years | |
| Bernhard Gentner | M | - | 10 years | |
| Guido Guidi | M | 71 | 7 years | |
| Leslie Trigg | F | 53 | 3 years | |
| Luigi Naldini | M | - | 10 years | |
| Hendrik Strydom | M | 64 | 2 years | |
| Lior Izhar | M | - |
Emendo Biotherapeutics, Inc.
Emendo Biotherapeutics, Inc. BiotechnologyHealth Technology Emendo Biotherapeutics, Inc. engages in the development of genome editing technology. It specializes in protein engineering, molecular biology, and gene editing systems. The company was founded by David Baram, Lior Izhar, and Rachel Diamant in 2015 and is headquartered in New York, NY. | 9 years |
| Roger Abravanel | M | 77 | 3 years | |
| Anthony Marucci | M | 62 | 3 years | |
| Todd Wider | M | - |
Xanadu Bio Inc.
| - |
| Debra Yu | M | 59 | 3 years | |
| Mike Gorley | M | 37 | 1 years | |
| Rachel Diamant | F | - |
Emendo Biotherapeutics, Inc.
Emendo Biotherapeutics, Inc. BiotechnologyHealth Technology Emendo Biotherapeutics, Inc. engages in the development of genome editing technology. It specializes in protein engineering, molecular biology, and gene editing systems. The company was founded by David Baram, Lior Izhar, and Rachel Diamant in 2015 and is headquartered in New York, NY. | 9 years |
| Tiziana Pollio | M | - | - | |
| Timothy J. Obara | M | - | 2 years | |
| Stefania Mazzoleni | M | 42 | 8 years | |
| Joseph Oved | M | - |
Emendo Biotherapeutics, Inc.
Emendo Biotherapeutics, Inc. BiotechnologyHealth Technology Emendo Biotherapeutics, Inc. engages in the development of genome editing technology. It specializes in protein engineering, molecular biology, and gene editing systems. The company was founded by David Baram, Lior Izhar, and Rachel Diamant in 2015 and is headquartered in New York, NY. | 2 years |
| Richard B. Slansky | M | 67 | 3 years | |
| Tetsuharu Yoneo | M | - |
Emendo Biotherapeutics, Inc.
Emendo Biotherapeutics, Inc. BiotechnologyHealth Technology Emendo Biotherapeutics, Inc. engages in the development of genome editing technology. It specializes in protein engineering, molecular biology, and gene editing systems. The company was founded by David Baram, Lior Izhar, and Rachel Diamant in 2015 and is headquartered in New York, NY. | - |
| Yoshinori Oikawa | M | - |
Emendo Biotherapeutics, Inc.
Emendo Biotherapeutics, Inc. BiotechnologyHealth Technology Emendo Biotherapeutics, Inc. engages in the development of genome editing technology. It specializes in protein engineering, molecular biology, and gene editing systems. The company was founded by David Baram, Lior Izhar, and Rachel Diamant in 2015 and is headquartered in New York, NY. | - |
| Robbie Woodman | M | 47 |
Emendo Biotherapeutics, Inc.
Emendo Biotherapeutics, Inc. BiotechnologyHealth Technology Emendo Biotherapeutics, Inc. engages in the development of genome editing technology. It specializes in protein engineering, molecular biology, and gene editing systems. The company was founded by David Baram, Lior Izhar, and Rachel Diamant in 2015 and is headquartered in New York, NY. | - |
| Erez Chimovits | M | 60 |
Emendo Biotherapeutics, Inc.
Emendo Biotherapeutics, Inc. BiotechnologyHealth Technology Emendo Biotherapeutics, Inc. engages in the development of genome editing technology. It specializes in protein engineering, molecular biology, and gene editing systems. The company was founded by David Baram, Lior Izhar, and Rachel Diamant in 2015 and is headquartered in New York, NY. | - |
| Ei Yamada | M | 74 |
Emendo Biotherapeutics, Inc.
Emendo Biotherapeutics, Inc. BiotechnologyHealth Technology Emendo Biotherapeutics, Inc. engages in the development of genome editing technology. It specializes in protein engineering, molecular biology, and gene editing systems. The company was founded by David Baram, Lior Izhar, and Rachel Diamant in 2015 and is headquartered in New York, NY. | 4 years |
| Carlo Russo | M | 71 | 3 years | |
| Duncan Moore | M | 65 | 3 years | |
| Carl Gordon | M | 59 |
Emendo Biotherapeutics, Inc.
Emendo Biotherapeutics, Inc. BiotechnologyHealth Technology Emendo Biotherapeutics, Inc. engages in the development of genome editing technology. It specializes in protein engineering, molecular biology, and gene editing systems. The company was founded by David Baram, Lior Izhar, and Rachel Diamant in 2015 and is headquartered in New York, NY. | - |
| Stephen P. Squinto | M | 67 |
Emendo Biotherapeutics, Inc.
Emendo Biotherapeutics, Inc. BiotechnologyHealth Technology Emendo Biotherapeutics, Inc. engages in the development of genome editing technology. It specializes in protein engineering, molecular biology, and gene editing systems. The company was founded by David Baram, Lior Izhar, and Rachel Diamant in 2015 and is headquartered in New York, NY. | - |
| Rob Ryan | M | 55 | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Kevin Conroy | M | 58 | 2 years | |
| Bradley Campbell | M | 48 | - | |
| Saqib Islam | M | 54 | 1 years | |
| Sanjiv Patel | M | 50 | 2 years | |
| Sergey Vasnetsov | M | 60 | 2 years | |
| Joshua Donfeld | M | - | 3 years | |
| Christine Silverstein | F | 41 |
Emendo Biotherapeutics, Inc.
Emendo Biotherapeutics, Inc. BiotechnologyHealth Technology Emendo Biotherapeutics, Inc. engages in the development of genome editing technology. It specializes in protein engineering, molecular biology, and gene editing systems. The company was founded by David Baram, Lior Izhar, and Rachel Diamant in 2015 and is headquartered in New York, NY. | - |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 34 | 75.56% |
| Italy | 11 | 24.44% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Todd Wider
- Personal Network
